Psilocybin and Multiple Sclerosis: Exploring Potential Benefits

Preclinical and early clinical research suggests psilocybin may have neuroprotective, anti‑inflammatory, immunomodulatory, and mood‑enhancing effects relevant to MS.

Potential Mechanisms

• 5‑HT2A agonism → neuroplasticity, BDNF upregulation.
• Reduction of pro‑inflammatory cytokines (IL‑6, TNF‑α).
• Modulation of microglial activation.
• Improvement in depression, anxiety, existential distress common in MS.

Current Status

• No large‑scale MS‑specific trials yet.
• Psilocybin remains Schedule I in many jurisdictions; access limited to research or special programs.
• Safety in MS unknown (theoretical seizure risk, cardiovascular effects).

Caution

Do not self‑medicate. Consult neurologist and psychiatrist; consider enrollment in clinical trials if available.